Plasmapheresis for Severe Autoimmune Urticaria: Advanced Clinical Realities

Chronic spontaneous urticaria (CSU) affects up to 1% of the population. A subset of these patients has severe autoimmune urticaria driven by autoantibodies against the high-affinity IgE receptor or IgE itself. When standard treatments fail, plasma exchange (plasmapheresis) can offer rapid relief by physically removing pathogenic factors from the blood. Below, we explore the clinical realities of plasmapheresis in severe autoimmune urticaria, including when it's used, how it works, and what patients should know.

Understanding Severe Autoimmune Urticaria

• Definition
– Chronic spontaneous urticaria: hives that last more than six weeks without an identifiable external trigger.
– Autoimmune subtype: up to 45% of CSU cases involve circulating autoantibodies.

• Symptoms
– Intense, itchy wheals (hives) lasting hours to days
– Angioedema (swelling of deeper layers of skin or mucosa)
– Significant impact on sleep, daily activities, and quality of life

• Standard Therapies
– High-dose non-sedating H1 antihistamines
– H2 antihistamines, leukotriene receptor antagonists
– Omalizumab (anti-IgE antibody)
– Cyclosporine A or other immunosuppressants

When these treatments fail or symptoms become life-threatening (e.g., laryngeal angioedema), clinicians may consider advanced therapies such as plasma exchange.

What Is Plasma Exchange (Plasmapheresis)?

Plasma exchange, commonly called plasmapheresis, is a blood purification technique designed to remove harmful components—such as autoantibodies, immune complexes, and inflammatory mediators—from the plasma.

1. Procedure Overview

   • Blood is withdrawn from the patient via a catheter.
   • A machine separates plasma (the liquid portion) from blood cells.
   • The patient's plasma is discarded and replaced with a substitute fluid (e.g., albumin solution or donor plasma).
   • Processed blood (cells plus replacement fluid) is returned to the patient.

2. Mechanism of Action

   • Rapidly lowers autoantibody levels in circulation.
   • Reduces complement activation and pro-inflammatory cytokines.
   • Provides fast symptomatic relief when conventional immunomodulators take weeks to act.

When to Consider Plasmapheresis

Plasma exchange is not first-line therapy. It is reserved for patients with:

• Severe, refractory autoimmune urticaria unresponsive to high-dose antihistamines and omalizumab.
• Life-threatening angioedema or systemic involvement.
• Markedly elevated autoantibody titers confirmed by laboratory testing.
• Rapidly worsening symptoms despite immunosuppressive therapy.

Decisions should be made by a multidisciplinary team (e.g., dermatologist, immunologist, transfusion medicine specialist).

Clinical Benefits

• Rapid Onset of Action
– Symptom improvement often begins within 24–48 hours.
– Hives may resolve completely for days to weeks after a session.

• Reduction in Autoantibodies
– Immediate drop in pathogenic autoantibody levels.
– Decreases mast cell and basophil activation.

• Bridging Therapy
– Can be used to stabilize patients while waiting for slower-acting treatments (e.g., cyclosporine) to take effect.

Risks and Side Effects

While generally safe in experienced hands, plasmapheresis carries potential risks:

• Vascular Access Complications:
  • Infection at catheter site
  • Bleeding or hematoma
  • Thrombosis (clot formation)

• Hypotension:
  • Sudden drop in blood pressure during plasma removal.
  • Usually managed by adjusting fluid removal rate or replacement fluid composition.

• Allergic Reactions:
  • Rare reactions to donor plasma or replacement solutions.
  • May require antihistamines or steroids.

• Electrolyte Imbalances:
  • Hypocalcemia from citrate anticoagulant used during the procedure.
  • Monitoring and calcium supplementation help prevent symptoms (e.g., tingling, muscle cramps).

• Infection Risk:
  • Transient decrease in immunoglobulins may slightly increase infection susceptibility.
  • Prophylactic antibiotics are not routinely recommended unless other risk factors exist.

Evidence Supporting Plasmapheresis

Several case reports and small series have demonstrated efficacy in severe autoimmune urticaria:

• A 2015 case series of 10 patients showed complete remission of hives after four to six sessions, with relapse in only two patients at six-month follow-up.
• A 2018 retrospective review reported 70% of refractory patients achieved significant symptom control after plasmapheresis plus omalizumab.

Large, randomized controlled trials are lacking due to the rarity of the condition and logistical challenges. However, expert consensus supports its use in life-threatening or highly refractory cases.

Practical Considerations

Before referring for plasma exchange, discuss the following with your care team:

• Availability:
  • Requires specialized apheresis centers with experienced staff.
  • Not all hospitals offer plasmapheresis.

• Cost and Insurance:
  • Procedures can be expensive; insurance coverage varies.
  • Pre-authorization is often needed.

• Treatment Schedule:
  • Typical protocol: 4–6 sessions over 1–2 weeks.
  • Maintenance sessions may be considered if symptoms recur.

• Patient Monitoring:
  • Vital signs, electrolyte levels, and complete blood counts are checked before and after each session.
  • Regular assessment of urticaria activity (e.g., Urticaria Activity Score) guides therapy adjustment.

Alternative and Adjunctive Treatments

Plasmapheresis may be combined with or followed by:

• Omalizumab (if not yet tried or dose-optimized)
• Cyclosporine A: 3–5 mg/kg/day under close monitoring of blood pressure and renal function
• Mycophenolate mofetil or methotrexate in select cases
• High-dose corticosteroids for short-term control of severe flares

Patient Perspective

Living with severe autoimmune urticaria can be challenging. Plasmapheresis offers:

• Swift relief from relentless hives
• A chance to reduce or stop high-dose steroids and their side effects
• Improved quality of life when other therapies have failed

However, the procedure demands time, vascular access, and careful follow-up.

Next Steps and Resources

If you or a loved one experiences unrelenting hives, swelling, or signs of systemic involvement, it's important to act promptly:

• Request a referral to a specialist experienced in apheresis therapies.
• Discuss risks, benefits, and logistical details with your care team.
• Before your appointment, use Ubie's free AI-powered Medically Approved Symptom Checker Chat Bot to document your symptoms and generate personalized questions to discuss with your physician.

Speak to a doctor immediately if you experience any of the following, as they could signal a life-threatening emergency:

• Difficulty breathing, swallowing, or speaking
• Rapid swelling of the face, lips, tongue, or throat
• Dizziness, fainting, or a drop in blood pressure
• Severe chest pain or palpitations

---

Plasmapheresis represents a powerful tool in the management of severe autoimmune urticaria when standard therapies fall short. By removing the very autoantibodies driving the disease, it can provide rapid, meaningful relief and bridge patients to longer-term treatments. As always, thorough discussion with your healthcare team and careful monitoring are essential to maximize benefits and minimize risks.